# Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.

> **NCT02745561** · PHASE2 · UNKNOWN · sponsor: **Hangzhou Cancer Hospital** · enrollment: 22 (estimated)

## Conditions studied

- Esophageal Cancer
- Endostatin

## Interventions

- **DRUG:** Endostatins
- **DRUG:** Oxaliplatin
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02745561
- **Lead sponsor:** Hangzhou Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2016-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02745561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02745561, "Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02745561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*